Currently, the main clinical application of liquid biopsy (LB) in breast cancer (BC) is the circulating tumor DNA (ctDNA)-based detection of treatment targets in metastatic or advanced disease. In this short review we focus on clinically relevant …
SMARCA4-deficient undifferentiated tumor (SMARCA4-UTs) is an extremely rare and aggressive entity where no consensus on systemic treatment exists to date. We report the case of a 43-year-old woman with thoracic SMARCA4-UT who presented with rapid …
verfasst von:
Petar Popov, Oskar Steinbrecher, Anke Scharrer, Markus Raderer, Thomas Brodowicz, Matthias Preusser, Wolfgang Lamm, MD
In recent years, there has been massive advances in the treatment of chronic lymphocytic leukemia (CLL) from chemoimmunotherapy to the combination of targeted agents (BTK inhibitors, BCL2 inhibitors, anti-CD20 antibody), which should be …
Clinical trials are subject to an ever-evolving landscape of treatment options, regulatory requirements, socioeconomic conditions, and paradigms of scientific research. In this opinion paper, we illustrate current methods and topics with a focus …
verfasst von:
Univ.-Prof. Prof.h.c. Dr. Dr.h.c. Michael Gnant, FACS, FEBS, Manuela Gili, Magdalena Schwarz, Christian Fesl, Dominik Hlauschek, Anita Jallitsch-Halper, Hannes Fohler
Cancer stem cells, also known as leukemic stem cells (LSC) in the context of leukemias, are an emerging topic in translational oncology and hematology. The Ludwig Boltzmann Institute for Hematology and Oncology (LBI HO) was established in 2008 …
verfasst von:
Peter Valent, M.D., Emir Hadzijusufovic, D.V.M., Irina Sadovnik, Ph.D., Thomas W. Grunt, Ph.D., Barbara Peter, D.V.M., Michael Willmann, D.V.M., Harald Herrmann, M.D., Daniel Ivanov, Ph.D., Gregor Eisenwort, M.D. Ph.D., Heidrun Karlic, Ph.D., Georg Greiner, M.D. Ph.D., Karoline V. Gleixner, M.D. Ph.D., Thomas Rülicke, Ph.D., Maik Dahlhoff, D.V.M., Philipp Staber, M.D. Ph.D., Wolfgang R. Sperr, M.D., Michael Pfeilstöcker, M.D., Thomas Lion, M.D. Ph.D. MSc., Felix Keil, Gregor Hoermann
Lung cancer remains the major reason of cancer-related deaths around the world, and non-small cell lung cancer (NSCLC) is nearly 85%, with adenocarcinoma being the most common histologic subtype [ 1 ]. Patients with stage IV lung adenocarcinoma are …
verfasst von:
Changbin Wang, Ran Zhang, Xiaorong Sun, Ligang Xing
Seminal vesicle metastasis from colon adenocarcinoma is very rare, with only two case reports in the literature [ 1 , 2 ]. We report a case of colon adenocarcinoma metastatic to the seminal vesicles discovered 6 years after the initial diagnosis …
verfasst von:
Juliana Arenas Hoyos, Julian Serrano Giraldo, Andres Felipe Gutierrez Rojas
Multiple Myeloma (MM) is characterized as an incurable, biologically heterogeneous disease of the plasma cells. It is defined by uncontrolled proliferation of monoclonal plasma cells in the bone marrow [ 1 ]. Bone marrow stromal cells (BMSC) are …
verfasst von:
Raika Naiebi, Saeid Abroun, Ph. D., Amir Atashi, Leila Shafiee, Mohammadarian Akbari, Mohammad Hasan Maleki, Morvarid Siri, M. Sc.
In non-small cell lung cancer (NSCLC), mutations within the epidermal growth factor receptor (EGFR) gene are very common driver mutations. EGFR tyrosine kinase inhibitors (TKIs), have shown remarkable efficacy in patients with common classical …
verfasst von:
Yana Sharapova, PhD, Sonja Loges, MD, PhD, Melanie Janning, MD
Pain management is a significant concern for cancer patients. Even in patients undergoing curative treatment, cancer pain can be severe. Because chemotherapy-induced neuropathic pain can persist even after treatment, searching for information …
verfasst von:
Kadriye Bir Yücel, MD, Osman Sutcuoglu, MD, Ozan Yazıcı, MD, Ahmet Ozet, MD, Nuriye Ozdemir, MD
Ovarian cancer (OC) management presents a challenging scenario in clinical practice due to its late diagnosis, high recurrence rate, and dismal 5‑year survival rate of 45%—especially in platinum-resistant cases. Antibody–drug conjugates (ADCs) are …
verfasst von:
Barin Feroz, Christian Marth, Alain Gustave Zeimet
In the last decade, the understanding of lung neoplasms, particularly rare salivary gland-type tumors (SGT), has deepened significantly. This review intends to spotlight the latest findings, particularly emphasizing the differentiation between …
Epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) generally has a favorable prognosis when compared to lung cancer without this alteration due to the advent of EGFR tyrosine kinase inhibitors (TKI). However, during …
verfasst von:
Nino Rafael Müser, Klaus Kirchbacher, Georg-Christian Funk
The annual meeting of the American Society of Medical Oncology (ASCO) was held as usual in Chicago, while the meeting focused on gastrointestinal tumors, ASCO-GI, was held in San Francisco. In particular, ASCO-GI included many phase III trials …
verfasst von:
Aysegül Ilhan-Mutlu, MD, PhD, Elisabeth Sophie Bergen, MD, PhD
Extragonadal germ cell tumors (EGCT) are rare and comprise only 2–3% of all testicular germ cell tumors. The majority of EGCT are located in the mediastinum, followed by the retroperitoneum. Although histologically similar to germ cell tumors …
verfasst von:
Prof. Dr. med. Axel Heidenreich, Pia Paffenholz, David Pfister
The 2023 annual meeting of the American Society of Clinical Oncology (ASCO) was again held in June 2023 in Chicago. While not immediately practice changing, results from several interesting studies in the field of breast cancer (BC) were reported.
Implementation of targeted drugs in the treatment landscape of indolent B‑cell malignancies has facilitated long-term remissions and reduced treatment-related toxicities for a substantial proportion of patients across several disease entities.
Acute myeloid leukemia (AML) is a highly heterogeneous malignant disorder characterized by the aberrant clonal proliferation of hematopoietic stem or progenitor cells. Approximately 60–80% of adult patients with AML achieve complete remission (CR) …
Despite the increasing number of patients with metastatic pancreatic adenocarcinoma (mPDAC) receiving second-line chemotherapy, little data have been reported about long-term survivors of mPDAC and prognostic factors. The study analyzes the …
